HOME > 研究紹介 > 発表論文 > 2021年


発表論文 - 2021年

  1. Abd-Alla HI, Souguir D, and Radwan MO.
    Genus Sophora: a comprehensive review on secondary chemical metabolites and their biological aspects from past achievements to future perspectives.
    Archives of Pharmacal Research 44: 903-986, 2021.
  2. Ciftci HI, Radwan MO, Sever B, Hamdy AK, Emirdag S, Ulusoy NG, Sozer E, Can M, Yayli N, Araki N, Tateishi H, Otsuka M, Fujita M, and Altintop MD.
    EGFR-targeted pentacyclic triterpene analogues for glioma therapy.
    International Journal of Molecular Sciences 22: 10945, 2021.
  3. Tateishi H, Tateishi M, Radwan MO, Masunaga T, Kawatashiro K, Oba Y, Oyama M, Inoue-Kitahashi N, Fujita M, Okamoto Y, and Otsuka M.
    A new inhibitor of ADAM17 composed of a zinc-binding dithiol moiety and a specificity pocket-binding appendage.
    Chemical & Pharmaceutical Bulletin 69: 1123-1130, 2021.
  4. Ciftci HI, Tateishi H, Koiwai K, Koga R, Anraku K, Monde K, Dag C, Destan E, Yuksel B, Ayan E, Yildirim G, Yigin M, Ertem FB, Shafiei A, Guven O, Besler SO, Sierra RG, Yoon CH, Su Z, Liang M, Acar B, Haliloglu T, Otsuka M, Yumoto F, Fujita M, Senda T, and DeMirci H.
    Structural insight into host plasma membrane association and assembly of HIV-1 matrix protein.
    Scientific Reports 11: 15819, 2021.
  5. Roshdy I, Mustafa M, Shaltout AE, Radwan MO, Fujita M, Otsuka M, and Ali TFS.
    Selective SIRT2 inhibitors as promising anticancer therapeutics: An update from 2016 to 2020.
    European Journal of Medicinal Chemistry 224: 113709, 2021.
  6. Ciftci HI, Bayrak N, Yildiz M, Yildirim H, Sever B, Tateishi H, Otsuka M, Fujita M, and Tuyun AF.
    Design, synthesis, and investigation of the mechanism of action underlying anti-leukemic effects of the quinolinequinones as LY83583 analogs.
    Bioorganic Chemistry 114: 105160, 2021.
  7. Yamaguchi Y, Kato K, Ichimaru Y, Jin W, Sakai M, Abe M, Wachino J, Arakawa Y, Miyagi Y, Imai M, Fukuishi N, Yamagata Y, Otsuka M, Fujita M, and Kurosaki H.
    Crystal structures of metallo-β-lactamase (IMP-1) and its D120E mutant in complexes with citrate and the inhibitory effect of the benzyl group in citrate mono-benzyl ester.
    Journal of Medicinal Chemistry 64: 10019-10026, 2021.
  8. Mohassab AM, Hassan HA, Abdelhamid D, Gouda AM, Gomaa HAM, Youssif BGM, Radwan MO, Fujita M, Otsuka M, and Abdel-Aziz M.
    New quinoline/1,2,4-triazole hybrids as dual inhibitors of COX-2/5-LOX and inflammatory cytokines: Design, synthesis, and docking study.
    Journal of Molecular Structure 1244: 130948, 2021.
  9. Bayrak N, Ciftci HI, Yildiz M, Yildirim H, Sever B, Tateishi H, Otsuka M, Fujita M, and Tuyun AF.
    Structure‐based design, synthesis, and evaluation of anti-CML activity of the quinolinequinones as LY83583 analogs.
    Chemico-Biological Interactions 345: 109555, 2021.
  10. 牧野雄成、大塚雅巳
    別冊Bio Clinica 慢性炎症と疾患 皮膚疾患と慢性炎症 122-127, 2021.
  11. Kamo M, Ito M, Toma T, Gotoh H, Shimozono R, Nakagawa R, Koga, R, Monde K, Tateishi H, Misumi S, Otsuka M, and Fujita M.
    Discovery of anti-cell migration activity of an anti-HIV heterocyclic compound by identification of its binding protein hnRNP M.
    Bioorganic Chemistry 107: 104627, 2021.
  12. Ichimaru Y, Kato K, Okuno Y, Yamaguchi Y, Jin W, Fujita M, Otsuka M, Imai M, and Kurosaki H.
    Design and synthesis of an anthranyl bridged optically active dinuclear iron(II)-ligand and evaluation of DNA-cleaving activity.
    Bioorganic Medicinal Chemistry Letters 35: 127782, 2021.
  13. Kato K, Ichimaru Y, Okuno Y, Yamaguchi Y, Jin W, Fujita M, Otsuka M, Imai M, and Kurosaki H.
    DNA-cleavage activity of the iron(II) complex with optically active ligands, meta- and para-xylyl-linked N',N'-dipyridylmethyl-cyclohexane-1,2-diamine.
    Bioorganic Medicinal Chemistry Letters 36: 127834, 2021.
  14. Mohassab AM, Hassan HA, Abdelhamid D, Gouda AM, Youssif BGM, Tateishi H, Fujita M, Otsuka M, and Abdel-Aziz M.
    Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAFV600E kinases.
    Bioorganic Chemistry 106: 104510, 2021.
  15. Mingle D, Ospanov M, Radwan MO, Ashpole N, Otsuka M, Ross SA, Walker LA, Abbas G, Shilabin, and Ibrahim MA.
    First in class (S,E)-11-[2-(arylmethylene)hydrazono]-PBD analogs as selective CB2 modulators targeting neurodegenerative disorders.
    Medicinal Chemistry Research 30: 98-108, 2021.
  16. Zeytun E, Altintop MD, Sever B, Ozdemir A, Ellakwa DE, Ocak Z, Ciftci HI, Otsuka M, Fujita M, and Radwan MO.
    A new series of antileukemic agents: Design, synthesis, in vitro and in silico evaluation of thiazole-based ABL1 kinase inhibitors.
    Anti-Cancer Agents in Medicinal Chemistry 21: 1099-1109, 2021.